Press Releases

Valo Health, LLC (Valo), has announced an exclusive drug discovery and development partnership with Global Genomics Group, (G3), giving Valo access to the largest and most-detailed cardio-metabolic dataset in the world. Since the inception of the partnership, Valo has identified subpopulations across the cardiometabolic spectrum that have not been resolved before now, and are leading to the discovery of underlying genetics, biomarkers, and new disease-modifying targets. Using its Opal Computa

Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its breast cancer vaccine. This breast cancer vaccine technology was invented and developed by Cleveland Clinic immunologist Dr. Vincent Tuohy, and his research team. Oncologist, Dr. Thomas Budd, also of Cleveland Cl

AbCellera (announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly’s trial, in collaboration with the state of New Mexico and major local institutions, will collect data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environme

Atomwise , a leader in the use of artificial intelligence (AI) for small molecule drug discovery, announced a partnership with FutuRx , a renowned biotechnology incubator based in Israel, focused on innovative therapeutic technologies in the early stages. The collaboration will serve as the first introduction of Atomwise's AtomNet® platform for AI-based drug discovery to a growing center for biotechnology innovation in Israel and is Atomwise's second partnership with a global incu

Janux Therapeutics, announced a strategic collaboration and license agreement with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize innovative, next generation T cell engager immunotherapies for the treatment of cancer. The goal of the collaboration is to use Janux’s proprietary Tumor Activated T Cell Engager (TRACTrTM) technology to engineer novel, T cell engager drug candidates directed against two cancer targets selected by Merck. Under

Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan. The 5th manufacturing building is a facility specifically designated for formulating anti-cancer drugs (total floor area: approximately 4,500m2). Since anti-cancer drugs are highly active, this building is designed to make it possible to manufacture anti-cancer agents more safely, with various preventive features for contr

Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer. The agreement not only opens up new opportunities for development of NK-antibody combination therapies but also has significant

Merus N.V., a clinical-stage oncology company developing innovative, full-length multi-specific antibodies (Biclonics® and TriclonicsTM), and Sema4, a patient-centered health intelligence company, announced they have entered into a strategic agreement to utilize Sema4’s advanced genomic testing to identify patients with tumors harboring neuregulin 1 gene (NRG1) fusions who may be eligible for investigational treatment with the bispecific antibody Zenocutuzumab (“Zeno”) i

TRIUMF, Canada’s particle accelerator centre, announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to actinium-225, a rare medical isotope that

Lexicon Pharmaceuticals, Inc., announced that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon’s patent rights for the compound. LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon. “In line with our realignment around the rapid development of the LX9211 program, we continue